Ir a las Transacciones
Private Equity | Salud

Saneca Pharmaceuticals has been acquired by AZC Group

Eterus Capital, a.s. has sold Saneca Pharmaceuticals, a.s. to AZC Group.

Saneca is a pharmaceutical contract manufacturing company active in the development, production, registration and distribution of generic medicines and active pharmaceutical ingredients. Saneca also owns a portfolio of cosmetics and generic products.

Based in Slovakia, AZC is an industrial business group operating in over 20 countries.

Founded in 2008, Eterus Capital is an investor targeting small and medium-sized companies with growth potential, that have successfully proved their business concept. The fund only invests in minority positions, while management control always remains in the hands of the original shareholders.

Oaklins’ team in Slovakia acted as the exclusive sell-side advisor in this transaction.

PARTES

Contáctese con el equipo de la transacción

Boris Kostik

Associate Partner
Bratislava, Eslovaquia
Oaklins WOOD & Co.

Lukáš Palaščák

Senior Manager
Bratislava, Eslovaquia
Oaklins WOOD & Co.

Transacciones relacionadas

Afric Phar has been acquired by Pharma Capital
Salud

Afric Phar has been acquired by Pharma Capital

Pharma Capital S.A. has acquired a significant stake in the Moroccan pharmaceutical group Afric Phar, which includes leading companies Afric Phar, Pharmis and Partner Lab, from the Chaoui family, in one of the largest transactions in the Moroccan pharmaceutical sector.

Ver más
Den Berk Délice accelerates growth through strategic partnership
Private Equity | Agricultura

Den Berk Délice accelerates growth through strategic partnership

Den Berk Délice, a leading Belgian grower of specialty tomatoes, has entered a strategic partnership with Egeria, an independent investment firm, to realize its next growth phase.

Ver más
Xiel Limited has been acquired by MIS Healthcare
Private Equity | Salud

Xiel Limited has been acquired by MIS Healthcare

MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.

Ver más